Aquestive Therapeutics, Inc.
AQST Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.00
KIRA · Stoqly’s AI analyst, in plain words
- Aquestive Therapeutics, Inc. had $44.5M of revenue in fiscal 2025, down 22.6% on the year before. Over five years, revenue changed −0.6% a year on average.
- Its operating margin was −159.5%, down 106.0 pts: of every 100 in sales, about −160 is left after running the business.
- Aquestive Therapeutics, Inc. lost $83.8M in fiscal 2025.
- Free cash flow was −$53.0M in fiscal 2025, −119.0% of revenue.
- Aquestive Therapeutics, Inc. has $66.2M more cash than debt.
Market cap
$500M
P/E
—
Revenue
$44.5M
Net income
−$83.8M
Free cash flow
−$53.0M
Operating margin
−159.5%
Aquestive Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−22.6%
No. Sales fell 22.6% last year.
Does it make a profit?
−188.1%
No. It lost money last year.
Does profit turn into cash?
−119.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aquestive Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- Aquestive Therapeutics, Inc.
- CIK
- 0001398733
Aquestive Therapeutics, Inc. · AQST
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $50.8M | $47.7M | $50.6M | $57.6M | $44.5M |
| Revenue growth | 10.9% | −6.2% | 6.1% | 13.8% | −22.6% |
| Gross margin | — | 59.3% | 58.8% | 69.0% | 58.3% |
| Operating margin | −68.2% | −88.2% | −29.9% | −53.5% | −159.5% |
| Net income | −$70.5M | −$54.4M | −$7.9M | −$44.1M | −$83.8M |
| Net margin | −138.8% | −114.1% | −15.6% | −76.7% | −188.1% |
| Diluted EPS | −$1.85 | −$1.12 | −$0.13 | −$0.51 | −$0.78 |
| Cash | |||||
| Cash from operations | −$33.0M | −$9.8M | −$6.4M | −$35.8M | −$52.4M |
| Capital expenditure | $0.9M | $1.0M | $1.0M | $0.2M | $0.6M |
| Free cash flow | −$33.9M | −$10.8M | −$7.4M | −$35.9M | −$53.0M |
| FCF margin | −66.7% | −22.7% | −14.6% | −62.4% | −119.0% |
| Share count change | 13.2% | 28.0% | 25.7% | 41.6% | 23.3% |
| Debt and strength | |||||
| Cash and short-term investments | $28.0M | $27.3M | $23.9M | $71.5M | $121M |
| Debt incl. finance leases | — | $33.4M | $45.0M | $45.0M | $55.0M |
| Shareholders' equity | −$82.1M | −$119M | −$106M | −$60.2M | −$33.7M |
| Current ratio | 2.2x | 1.0x | 2.2x | 4.7x | 3.1x |
| Interest coverage | −3.5x | −6.4x | −2.4x | −2.8x | −6.4x |
| Returns and quality | |||||
| Piotroski F-score | 3 | 3 | 4 | 4 | 2 |
| Altman Z'' | −15.2 | −23.4 | −18.0 | −9.6 | −8.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.4M
8 insiders
Of sales under plans
31%
$0.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aquestive Therapeutics, Inc. · AQST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.00 a share, the company is worth $500M.
Source: SEC EDGAR XBRL filings (CIK 0001398733). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.